Journal
EXPERIMENTAL DERMATOLOGY
Volume 31, Issue 4, Pages 485-497Publisher
WILEY
DOI: 10.1111/exd.14541
Keywords
benvitimod; coal; oxidative; soybean; tapinarof; tar
Categories
Ask authors/readers for more resources
The AHR/NRF2 modulation pathway shows promise in the treatment of atopic dermatitis and other inflammatory skin disorders by impacting epidermal barrier function, immunomodulation, oxidative stress reduction, and cutaneous microbiome modulation.
Aryl hydrocarbon receptor (AHR)/nuclear factor-erythroid 2-related factor 2 (NRF2) modulation is emerging as novel targets in the treatment of atopic dermatitis and other inflammatory skin disorders. Agonist activation of this pathway has downstream effects on epidermal barrier function, immunomodulation, oxidative stress reduction and cutaneous microbiome modulation. Tapinarof, a dual agonist of the AHR/NRF2 signalling pathway, has shown promise in phase 2 trials for atopic dermatitis. In this review, we summarize current knowledge of the AHR/NRF2 pathway and implications in skin disease process. We also review the therapeutic potential of current AHR agonists and propose future directions to address knowledge gaps.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available